Gastrointestinal Stromal Tumors Therapeutics Market by Route of Administration and Geography - Forecast and Analysis 2022-2026

The gastrointestinal stromal tumors therapeutics market share is expected to increase by USD 1.08 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 5.97%.

This gastrointestinal stromal tumors therapeutics market research report provides valuable insights on the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers the gastrointestinal stromal tumors therapeutics market segmentation by route of administration (oral and parenteral) and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The gastrointestinal stromal tumors therapeutics (GIST) market report also offers information on several market vendors, including Ascentage Pharma Group International, AB Science SA, Bayer AG, Blueprint Medicines Corp, Bristol Myers Squibb Co., Deciphera Pharmaceuticals Inc, Immunicum AB, NATCO Pharma Ltd., Novartis AG, Pfizer Inc., Sumitomo Pharma Oncology Inc., Sun Pharmaceutical Industries Ltd, Xencor Inc., and Arog Pharmaceuticals Inc among others.

What will the Gastrointestinal Stromal Tumors Therapeutics Market Size be During the Forecast Period?

Download Report Sample to Unlock the Gastrointestinal Stromal Tumors Therapeutics Market Size for the Forecast Period and Other Important Statistics

Gastrointestinal Stromal Tumors Therapeutics Market: Key Drivers, Trends, and Challenges

Our researcher studied the historical data for years, with 2021 as the base year and 2022 as the estimated year, and produced drivers, trends, and challenges for the gastrointestinal stromal tumors therapeutics market. During the COVID-19 pandemic, the gastrointestinal stromal tumors therapeutics market demand has been impacted greatly. A holistic analysis of drivers will help exact demands and refine marketing strategies to gain a competitive advantage.

Key Gastrointestinal Stromal Tumors Therapeutics Market Driver

• The growing geriatric population is one of the key factors driving the gastrointestinal stromal tumors therapeutics (GIST) market growth.
• The risk of a person developing the disease increases with age. The advances in healthcare infrastructure and the increasing number of treatment options available for various indications, such as cancer, have increased the life expectancy of people globally. 
• Factors such as increasing awareness about various life-threatening indications have been contributing to higher life expectancy. 
• Developing countries such as China, India, and Brazil are some of the fastest-growing countries in terms of the geriatric population. Factors such as the high population and the rapid advances in healthcare infrastructure in these countries are expected to further contribute to geriatric population growth. This, in turn, will drive market growth during the forecast period.

Key Gastrointestinal Stromal Tumors Therapeutics Market Trend

• The advent of regenerative therapy is one of the key gastrointestinal stromal tumors therapeutics (GIST) market trends fueling the market growth.
• A surgical procedure does not remove the tumor completely. As a result, therapeutics are often used as adjuvant therapy to treat the remaining portion of the tumor. Even after the complete removal of the tumor, the disease is known to recur in the future.
• Research shows that various genes are associated with the progression of gastrointestinal stromal tumors. Some of the common genes that are known to cause cancer in the gastric tract are the KIT gene and the PDGFRA gene.
• As a good proportion of the patient population becomes resistant to the treatment using GLEEVEC, SUTENT, and STIVARGA, the market witnesses a huge demand for personalized treatment options. 
• The identification of gene mutation is leading to advances in therapeutics development, as various researchers are studying the use of gene therapy for the treatment of these tumors. Such factors will fuel market growth in the near future.

Key Gastrointestinal Stromal Tumors Therapeutics Market Challenge

• High treatment costs are one of the factors limiting the gastrointestinal stromal tumors therapeutics (GIST)  market growth.
• A major share of the global gastrointestinal stromal tumors therapeutics market is dominated by specialty drugs such as GLEEVEC, STIVARGA, and SUTENT, which contribute to approximately 70% of the market revenue. 
• For instance, treatment using GLEEVEC costs $110,000-$120,000 per year or $9,000-$10,000 per month. Hence, many patients who do not have health insurance or access to patient assistance programs from vendors or governments do not adhere to treatment regimens, which reduces patient adherence and poses a challenge to market growth. 
• Although the prices of generic drugs often decrease over time, with multiple generic versions entering the market, the global gastrointestinal stromal tumors therapeutics market will not likely be impacted by this threat until the late second half of the forecast period. 
• The complex manufacturing process and high R&D costs of biologics often lead to vendors offering these drugs at a high price. The high treatment costs using therapeutics are expected to be one of the major challenges to the market's growth during the forecast period.

This gastrointestinal stromal tumors therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global gastrointestinal stromal tumors therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the gastrointestinal stromal tumors therapeutics market during the forecast period.

Who are the Major Gastrointestinal Stromal Tumors Therapeutics Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

• Ascentage Pharma Group International
• AB Science SA
• Bayer AG
• Blueprint Medicines Corp
• Bristol Myers Squibb Co.
• Deciphera Pharmaceuticals Inc
• Immunicum AB
• NATCO Pharma Ltd.
• Novartis AG
• Pfizer Inc.
• Sumitomo Pharma Oncology Inc.
• Sun Pharmaceutical Industries Ltd
• Xencor Inc.
• Arog Pharmaceuticals Inc

This statistical study of the GIST therapeutics market encompasses successful business strategies deployed by the key vendors. The GIST therapeutics market is concentrated, and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

• oncology.sumitomo-pharma.com - The company offers gastrointestinal stromal tumors therapeutics such as antihypertensive therapy and Sutent.

To make the most of the opportunities and recover from the post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The vendor profiles are designed to help clients improve their market position and information on production and sustainability along with this the report provides a detailed analysis of several leading Companies.

Gastrointestinal Stromal Tumors Therapeutics Market Value Chain Analysis

Our In-house experts produce extensive information on the value chain and parent market of the gastrointestinal stromal tumors therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The Value Chain information provides an end-end understanding of product insight and profits and also optimization and evaluation of business strategies The players across the value chain include selective data and analysis from entire research findings as per the scope of the report.

Which are the Key Regions for the Gastrointestinal Stromal Tumors Therapeutics Market?

For more insights on the market share of various regions Request PDF Sample now!

37% of the market’s growth will originate from North America during the forecast period. The US is the key market for the gastrointestinal stromal tumors therapeutics market in North America. Market growth in this region will be slower than the growth of the market in other regions.

The world's largest pharmaceutical market will facilitate the gastrointestinal stromal tumors therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID-19 Impact and Recovery Analysis

The outbreak of COVID-19 severely impacted the regional market in North America in 2020. However, with the initiation of vaccination drives and government initiatives in 2021, the market started recovering from the impact of the pandemic on growth. Owing to these factors, the regional market is expected to grow significantly during the forecast period.

What are the Revenue-generating Route of Administration Segments in the Gastrointestinal Stromal Tumors Therapeutics Market?

To gain further insights on the market contribution of various segments Request a PDF Sample

The gastrointestinal stromal tumors therapeutics market share growth by the oral segment will be significant during the forecast period. The oral segment is expected to witness a number of generic drugs entering the market. Despite the expected volume growth, the entry of generics is expected to cause value erosion, owing to their low prices. This is expected to result in the oral segment losing some of its market share to the parenteral segment. However, the demand for these drugs is expected to remain higher than that for parenteral drugs during the forecast period, which results in a partial offset of the damage caused.

This report provides an accurate prediction of the contribution of all the segments to the growth of the GIST therapeutics market size and actionable market insights on the post-COVID-19 impact on each segment.

Request PDF sample

What are the Key Data Covered in this Gastrointestinal Stromal Tumors Therapeutics Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive gastrointestinal stromal tumors therapeutics market growth during the next five years
• Precise estimation of the gastrointestinal stromal tumors therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the gastrointestinal stromal tumors therapeutics industry across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of gastrointestinal stromal tumors therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch